One of the diseases that poses a serious risk of death is bone cancer. There is a considerable tendency for many common malignancies, such as those of the breast, prostate, kidney, and lung, to metastasis to bones, particularly the ribs, hip, femur, and tibia.
According to NIH, about 5% of children have cancer and 0.2% of all cancers are primary bone cancers (PBC), which is still a rare disease. 1,720 PBC deaths are expected in 2020 in the United States, accounting for 0.3% of all cancer-related deaths. An assessed 3,600 new cases of primary bone cancer will be diagnosed. Adults with chondrosarcoma (40%) and osteosarcoma (28%), respectively, are most likely to get these two cancers. Osteosarcoma (56%) and Ewing sarcoma (34%) are the two most frequent sarcomas in children and adolescents. Less frequently occurring PBC forms include chordoma, undifferentiated pleomorphic sarcoma, adamantinoma, fibrosarcoma, and giant cell tumors of the bone. The global osteosarcoma male-to-female ratio is 1.43 to 1, indicating a prevalence of males in PBC.
A variety of malignancies that arise in the bones are referred to as bone cancers. Normal bone tissue is harmed by cancer cells that proliferate in bones. The type of bone cancer depends on the kind of cell and tissue that develops cancer.
Primary bone malignancies refer to cancers that originate inside the bone. Numerous cancers that originate in organs or other body parts often metastasize to the bones in addition to other body parts. These tumors are referred to as metastatic or secondary bone malignancies. Most frequently, lung, prostate, and breast cancers metastasis (spread) to the bones.
The tumor's location and size, as well as whether the disease has progressed to other regions, are factors in staging. There are four phases of primary bone cancer. In stage 1 the cancer cells are still confined, and the tumor is low-grade. Stage 2 is where the tumor is high-grade, but the cancer cells are still confined. In stage 3 disease has spread to other parts of the same bone and the tumor is high-grade. Stage 4 is when cancer has progressed from the bone to the liver or lungs, among other parts of the body.
Primary bone cancer is classified into four types:
Osteosarcoma: The most prevalent kind of bone cancer, osteosarcoma begins in the cells that produce new bone. Though it commonly starts at the extremities of big bones, such as the arms and legs, it originates in any bone. Osteosarcoma in children and teenagers is most frequently diagnosed by providers.
Ewing sarcoma: It is named after the physician who was the first to report this kind of bone cancer, Ewing sarcoma is a broad category that covers a variety of tumors with similar characteristics that are thought to start in the same cells. These tumors develop in the soft tissues and bones nearby. The hips, ribs, shoulder blades, and long bones like the legs are the most typical locations for Ewing sarcoma growth. Roughly 85% of Ewing sarcomas have the EWSR1/FLI1 fusion gene.
Chondrosarcoma: Cartilage is the first tissue in which chondrosarcoma develops. The soft connective tissue known as cartilage facilitates mobility between bones and joints. The body converts some cartilage to bone by adding calcium to it. The arm, leg, or pelvic bones are where this cancer usually first appears. In contrast to osteosarcoma and Ewing sarcoma, chondrosarcoma affects adults more often than children.
Chordoma: Usually near the base of the skull or the base of the spine, this uncommon tumor starts in the bones of the spine. Like chondrosarcoma, chordoma primarily affects elderly persons. This kind of bone cancer affects men more often than women.
Imaging Tests
Tissue Sampling
Diagnostic Market Players |
|
Imaging Test |
Tissue Sampling |
Canon Medical Systems Corporation |
Becton, Dickinson, and Company (BD) |
Hitachi, Ltd. |
Foundation Medicine, Inc. |
Toshiba Corporation |
Danaher Corporation |
Siemens Healthineers |
Genomic Health, Inc. |
Philips Healthcare |
Biocept, Inc. |
Shimadzu Corporation |
Guardant Health, Inc. |
Thermo Fisher Scientific |
Biodesix, Inc |
Bristol-Myers Squibb Company |
Hologic, Inc. |
Esaote S.p.A. |
Roche Diagnostics |
Neusoft Medical Systems Co., Ltd. |
Abbott Laboratories |
Mindray Medical International Limited |
|
Genomic Health, Inc. |
|
Agilent Technologies, Inc. |
|
General Electric Company (GE Healthcare) |
|
Diagnosis Products |
|
Imaging Tests |
Tissue Sampling |
SIGNA™ Architect |
Affirm™ |
Optima™ CT |
Cobas® |
MAGNETOM® |
Aptima™ |
Vereos™ |
Phadia™ |
Discovery™ CT |
RealTime® |
SIGNA™ MRI |
Cellient™ |
SIGNA™ Pioneer |
ARCHITECT® |
Revolution™ CT |
Alinity™ |
Discovery™ PET/CT |
VENTANA |
Gemini™ |
CytoLyt® |
VUE Point™ FX |
ThinPrep® |
Discovery™ MI |
BD SurePath™ |
SOMATOM® |
BD Vacutainer® |
Biograph® |
BD Vacutainer® |
Brilliance™ |
Oncomine™ |
Radiation therapy, chemotherapy, surgery, and other progressive therapies are available for the treatment of primary bone cancer. They are used alone or in combination. The recommended course of treatment is contingent upon the nature, extent, and position of the tumor in addition to age and overall health.
Surgery
Surgery is the process of operating to remove a tumor along with some surrounding tissue. A physician who specializes in bone cancer surgery is known as an orthopedic oncologist.
During limb-sparing surgery, medical professionals employ several procedures to preserve the child's use of the tumor-affected arm or leg while also restoring the limb's normal appearance. Reconstructive surgery and bone grafting are surgical methods. A bone allograft replaces and repairs damaged bone by using bone from another person. Metal allografts are used in most reconstructions. Children and teenagers with osteosarcoma are most frequently treated with limb-sparing surgery. Occasionally, the procedure that yields the strongest and most functional limb is not always the same as the one that yields the most normal appearance. A bone marrow transplant (BMT) involves taking out a patient's bone marrow and either transferring the blood-forming cells to another person or returning the bone marrow to the original patient later.
Chemotherapy
Chemotherapy involves using medications to kill cancer cells, usually by preventing the cells from proliferating, dividing, or developing into new ones. Chemotherapy, often known as systemic therapy, is administered into the bloodstream to target cancer cells throughout the body. It is often administered orally (as a tablet) or by an intravenous (IV) tube inserted into a vein with a needle. Systemic chemotherapy is most often administered to adolescents and teenagers with high-grade osteosarcoma. Without systemic chemotherapy, the survival rate for patients with localized, high-grade osteosarcoma is less than 20%, however, it reaches 50% to 75% with chemotherapy.
Radiation Therapy
High-energy X-rays or other particles are used in radiation treatment to kill cancer cells. A radiation oncologist is a medical professional who specializes in administering radiation treatment to treat cancer. External-beam radiation therapy is typically utilized as a radiation treatment for osteosarcoma. This is radiation therapy administered externally, via a machine. A radiation therapy programmed, or regimen, often entails a predetermined number of treatments administered over a predetermined length of time.
It is rare to use radiation therapy for osteosarcoma. This is due to radiation therapy's relative ineffectiveness against osteosarcoma. Most patients whose osteosarcoma cannot be surgically excised or if some of the tumor persists after surgery are candidates for radiation therapy.
Some common type of radiation therapies includes –
Drug Therapy
Kinase inhibitors are prescription drugs used in the treatment of certain types of bone cancer. Proteins in the cell (or on its surface) called kinases are generally responsible for relaying signals, instructing the cell to proliferate. In some cases, blocking specific kinases helps stop or reduce the growth of cancers.
The most common uses for these medications are in the treatment of chordomas that have spread or returned following therapy. Advanced Chondrosarcomas: These medications are also used to treat them.
Treatment Market Players |
Radiation Therapy |
Chemotherapy |
Drug Therapy |
Varian Medical Systems |
Siemens Healthineers |
Pfizer Inc. |
Elekta |
Thermo Fisher Scientific Inc. |
Amgen Inc. |
Accuray |
GE Healthcare |
Novartis AG |
Siemens Healthineers |
Halyard Health, Inc. |
Eli Lilly and Company |
ViewRay |
Mevion Medical Systems |
Merck & Co |
Mitsubishi Electric Corporation |
Becton, Dickinson, and Company |
Bayer AG |
Hitachi, Ltd. |
Stryker Corporation |
Bristol-Myers Squibb Company, |
Brainlab AG |
Varian Medical Systems |
Takeda Pharmaceutical |
Best Theratronics Ltd |
|
F. Hoffmann-La Roche Ltd |
|
|
AstraZeneca PLC |
|
|
Gilead Sciences, Inc. |
Treatment Products |
||
Radiation Therapy |
Chemotherapy |
Drug Therapy |
MRIdian™ |
BD Plastipak™ Syringe pump |
Gleevec® |
ARTISTE™ |
Alaris™ Pump module |
Sprycel® |
ProBeam® |
SIGMA Spectrum® Infusion System |
Sutent® |
PRIMUSTM |
Alaris™ Syringe module |
Tarceva® |
|
BD Alaris™ gravity set |
Tykerb® |
TrueBeam® |
Alaris™ PC unit |
Nexavar® |
ExacTrac® |
BD Alaris™ Pump module set |
Stivarga® |
Halcyon® |
BD Alaris™ Syringe module set |
Votrient® |
VitalBeam® |
BD Nexiva™ |
Doxorubicin |
ARIA® |
BD Angiocath™ |
Cisplatin |
Eclipse™ |
BD Insyte™ |
Ifosfamide |
HyperArc™ |
BD Introsyte™ |
|
Edge® |
BD Introsyte™ |
|
MRIdian Cobalt |
BD CareFusion™ Syringe pump |
|
Siemens Primus Linear Accelerator |
ARROW® Catheters |
|
DiseaseLandscape Insights (DLI) consultancy firm provides valuable support in future market trends on the development of new pharmaceutical products. This support helps to streamline the planning and execution of clinical trials of novel medications and treatments, implement effective patient recruitment strategies, ensure regulatory compliance, and increase the likelihood of successful trial outcomes.
Phase 1 |
Phase 2 |
Phase 3 |
Phase 4 |
Losartan + Sunitinib in Treatment of Osteosarcoma |
Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial |
Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) |
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents with Giant Cell Tumor of the Bone |
Phase Ib / Regorafenib with Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma |
Mifamurtide Combined with Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients |
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements. |
Clinical Trial of Lithium Carbonate Combined with Neo-adjuvant Chemotherapy to Treat Osteosarcoma |
A Dose Finding Study to Treat Bone Tumor(s) |
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage |
Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure |
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients with Oral Cavity or Skull Base Tumors |
A Study of ZN-c3 in Combination with Gemcitabine in Subjects with Osteosarcoma |
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma |
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years with Primary Bone Tumors |
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases from Either Breast or Castration-resistant Prostate Cancer |
A Phase I Feasibility and Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells in Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma |
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults with Recurrent or Metastatic Osteosarcoma, TACOS Study |
Prevention of Symptomatic Skeletal Events with Denosumab Administered Every 4 Weeks Versus Every 12 Weeks |
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients with Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH |
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants with Recurrent or Refractory Osteosarcoma |
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) |
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma |
|
Natalizumab in Recurrent, Refractory, or Progressive Pulmonary Metastatic Osteosarcoma |
|
18F-Sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment |
|
DiseaseLandscape Insights (DLI) assists manufacturers in developing and implementing viable remedies to interrupt and manage Crohn’s Disease outbreaks. Furthermore, there is an increasing need for diagnostic tools, clinical evaluations, and innovative therapies because of greater awareness and estimated epidemics.
DiseaseLandscape Insights offers essential knowledge and expertise to major stakeholders involved in the manufacture of therapeutic goods. DiseaseLandscape Insights' support makes it easier for market participants to organize and carry out clinical trials for innovative medicines and pharmaceuticals, patient recruiting tactics, and regulatory compliance.
Ultimately, this encourages the leaders to perform qualitative research, explore the manufacturing organizations, and learn about raw material suppliers. DLI services assist all industry players to stay one step ahead and obtain a stronger foothold in the Bone Cancer.
How we can help?